Receive a weekly summary and discussion of the top papers of the week by leading researchers in the field.

In Hepatology (Baltimore, Md.)

BACKGROUND & AIMS : Manual histologic assessment is currently the accepted standard for diagnosing and monitoring disease progression in nonalcoholic steatohepatitis (NASH), but is limited by variability in interpretation and insensitivity to change. Thus, there is a critical need for improved tools to assess liver pathology in order to risk stratify NASH patients and monitor treatment response.

APPROACH & RESULTS : Here, we describe a machine learning (ML)-based approach to liver histology assessment, which accurately characterizes disease severity and heterogeneity, and sensitively quantifies treatment response in NASH. We utilize samples from three randomized controlled trials to build and then validate deep convolutional neural networks to measure key histologic features in NASH including steatosis, inflammation, hepatocellular ballooning, and fibrosis. The ML-based predictions showed strong correlations with expert pathologists and were prognostic of progression to cirrhosis and liver-related clinical events. We developed a new heterogeneity-sensitive metric of fibrosis response, the Deep Learning Treatment Assessment (DELTA) Liver Fibrosis score, which measured anti-fibrotic treatment effects that went undetected by manual pathological staging and was concordant with histologic disease progression.

CONCLUSIONS : Our ML method has shown reproducibility, sensitivity, and was prognostic for disease progression demonstrating the power of ML to advance our understanding of disease heterogeneity in NASH, risk stratify affected patients, and facilitate the development of novel therapies.

Taylor-Weiner Amaro, Pokkalla Harsha, Han Ling, Jia Catherine, Huss Ryan, Chung Chuhan, Elliott Hunter, Glass Benjamin, Pethia Kishalve, Carrasco-Zevallos Oscar, Shukla Chinmay, Khettry Urmila, Najarian Robert, Taliano Ross, Subramanian G Mani, Myers Robert P, Wapinski Ilan, Khosla Aditya, Resnick Murray, Montalto Michael C, Anstee Quentin M, Wong Vincent Wai-Sun, Trauner Michael, Lawitz Eric J, Harrison Stephen A, Okanoue Takeshi, Romero-Gomez Manuel, Goodman Zachary, Loomba Rohit, Beck Andrew H, Younossi Zobair M

2021-Feb-11

cirrhosis, fibrosis, pathology, risk stratification, scoring